Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2015

View Archived Issues

Symic Biomedical selects vascular clinical candidate SBCV-030

Evolocumab becomes first PCSK9 inhibitor approved in the world

FDA grants breakthrough therapy designation to BMS-663068

NEI starts phase I/II clinical study of AAV8-RS1 gene therapy for XLRS

OAT-449 shows in vitro efficacy as a microtubule-destabilizing compound

Verva Pharmaceuticals agrees to sell IP, appoints liquidator

Spero Therapeutics receives first milestone payment under Roche anti-infectives collaboration

JCR Pharmaceuticals and Eisai sign J-Brain Cargo feasibility agreement

Emergent BioSolutions awarded BARDA contract to develop and manufacture Ebola antibodies

New potential biomarkers for early-stage AD

Forge Therapeutics enters metalloprotein inhibitor pilot study with Janssen

Isis Pharmaceuticals begins phase I/IIa trial of ISIS-HTTRx in Huntington's disease

Panoptes' nonsteroidal drug presented for inflammatory eye diseases

Tekmira to change name, focus on HBV

Merck Patent discloses PARP-1 and/or TNKS-1 and/or TNKS-2 inhibitors

OncoTartis patents compounds for leukemia

Purdue Pharma reports kappa- and mu-opioid agonists

Cytox and Affymetrix partner to develop blood test for Alzheimer's disease risk

Shionogi develops P2X7 antagonists

Cephalon reports AXL and HGFR kinase inhibitors

AstraZeneca reports results from phase III trial of selumetinib in uveal melanoma

Novel mechanism of cone protection by rod-derived cone viability factor identified

Therabron Therapeutics updates on phase IIa trial of CG-100 in bronchopulmonary dysplasia

Nippon Kayaku's infliximab biosimilar approved for new indication in Japan

Mongersen receives FDA orphan drug designation for pediatric Crohn's disease

AstraZeneca initiates phase IIa study of inhaled interferon-beta for severe asthma

Ablynx and Merck & Co. expand Nanobody collaboration in immuno-oncology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...